Ardelyx (ARDX) Receivables - Net (2013 - 2026)
Ardelyx's (ARDX) quarterly Receivables - Net came in at $82.8 million in Q1 2026, up 78.28% YoY from $46.5 million in Q1 2025, and up 15.3% on a QoQ basis from $71.8 million in Q4 2025.
Ardelyx (ARDX) Receivables - Net (2013 - 2026) Analysis & Trends
Ardelyx (ARDX) has 12 years of Receivables - Net data on file, last reported at $82.8 million in Q1 2026.
- Quarterly Receivables - Net rose 78.28% year-over-year to $82.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $82.8 million (up 78.28% YoY) and the FY2025 annual result came in at $71.8 million, up 24.51% from the prior year.
- Receivables - Net improved to $82.8 million in Q1 2026, from $71.8 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $82.8 million in Q1 2026 to a low of $4.4 million in Q1 2022.
- A 5-year average of $36.8 million and a median of $37.2 million in 2024 frame the typical range for Receivables - Net.
- The widest YoY moves for Receivables - Net: up 1714.63% in 2022, down 24.02% in 2022.
- Tracing ARDX's Receivables - Net over 5 years: stood at $7.7 million in 2022, then jumped by 184.9% to $22.0 million in 2023, then surged by 161.93% to $57.7 million in 2024, then rose by 24.51% to $71.8 million in 2025, then climbed by 15.3% to $82.8 million in 2026.
- The last three Receivables - Net figures came in at $82.8 million (Q1 2026), $71.8 million (Q4 2025), and $76.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 100.35 Mn |
| Jun 30, 2026 | 100.35 Mn |
| Mar 31, 2026 | 82.84 Mn |
| Mar 31, 2026 | 82.84 Mn |
| Dec 31, 2025 | 71.85 Mn |
| Dec 31, 2025 | 71.85 Mn |
| Sep 30, 2025 | 76.61 Mn |
| Sep 30, 2025 | 76.61 Mn |
| Jun 30, 2025 | 62.55 Mn |
| Jun 30, 2025 | 62.55 Mn |
| Mar 31, 2025 | 46.47 Mn |
| Mar 31, 2025 | 46.47 Mn |
| Dec 31, 2024 | 57.71 Mn |
| Dec 31, 2024 | 57.71 Mn |
| Sep 30, 2024 | 53.20 Mn |
| Sep 30, 2024 | 53.20 Mn |
| Jun 30, 2024 | 37.24 Mn |
| Jun 30, 2024 | 37.24 Mn |
| Mar 31, 2024 | 28.16 Mn |
| Mar 31, 2024 | 28.16 Mn |